Calvo Dulce Maria, Saiz Luis Carlos, Leache Leire, Celaya Maria Concepción, Gutiérrez-Valencia Marta, Alonso Alvaro, Erviti Juan, Alzueta Natalia, Echeverría Amaya, Garjón Javier, Fontela Carmen, Sanz Lorea, Acín Maria Teresa, Fernández Maria Loreto, Gómez Nerea
Autonomous University of Barcelona (UAB), Barcelona, Spain.
Unit of Innovation and Organization, Navarre Health Service, Navarra Health Research Institute (IdiSNA), Pamplona, Spain.
Pharmacoepidemiol Drug Saf. 2023 Aug;32(8):898-909. doi: 10.1002/pds.5621. Epub 2023 Apr 5.
Concomitant use of diuretics, renin-angiotensin-aldosterone system (RAAS) inhibitors, and non-steroidal anti-inflammatory drugs (NSAIDs) or metamizole, known as 'triple whammy' (TW), has been associated with an increased risk of acute kidney injury (AKI). Nevertheless, there is still uncertainty on its impact in hospitalisation and mortality. The aim of the study was to analyse the association between exposure to TW and the risk of hospitalisation for AKI, all-cause mortality and the need for renal replacement therapy (RRT).
A case-control study nested in a cohort of adults exposed to at least one diuretic or RAAS inhibitor between 2009 and 2018 was carried out within the Pharmacoepidemiological Research Database for Public Health Systems (BIFAP). Patients hospitalised for AKI between 2010 and 2018 (cases) were matched with up to 10 patients of the same age, sex and region of Spain who had not been hospitalised for AKI as of the date of hospitalisation for AKI of the matching case (controls). The association between TW exposure versus non-exposure to TW and outcome variables was analysed using logistic regression models.
A total of 480 537 participants (44 756 cases and 435 781 controls) were included (mean age: 79 years). The risk of hospitalisation for AKI was significantly higher amongst those exposed to TW [adjusted odds ratio (aOR) 1.36, 95% confidence interval (95%CI) 1.32-1.40], being higher with current (aOR 1.60, 95%CI 1.52-1.69) and prolonged exposure (aOR 1.65, 95%CI 1.55-1.75). No significant association was found with the need of RRT. Unexpectedly, mortality was lower in those exposed to TW (aOR 0.81, 95%CI 0.71-0.93), which may be influenced by other causes.
Vigilance should be increased when diuretics, RAAS inhibitors, and NSAIDs or metamizole are used concomitantly, especially in patients at risk such as elderly patients.
利尿剂、肾素 - 血管紧张素 - 醛固酮系统(RAAS)抑制剂与非甾体抗炎药(NSAIDs)或安乃近联合使用,即所谓的“三重打击”(TW),与急性肾损伤(AKI)风险增加相关。然而,其对住院率和死亡率的影响仍存在不确定性。本研究的目的是分析TW暴露与AKI住院风险、全因死亡率以及肾脏替代治疗(RRT)需求之间的关联。
在公共卫生系统药物流行病学研究数据库(BIFAP)中开展了一项病例对照研究,该研究嵌套于2009年至2018年间至少暴露于一种利尿剂或RAAS抑制剂的成年队列中。2010年至2018年间因AKI住院的患者(病例)与年龄、性别和西班牙地区相同且截至匹配病例因AKI住院日期尚未因AKI住院的多达10名患者(对照)进行匹配。使用逻辑回归模型分析TW暴露与未暴露于TW和结局变量之间的关联。
共纳入480537名参与者(44756例病例和435781名对照)(平均年龄:79岁)。暴露于TW的患者中,AKI住院风险显著更高[调整优势比(aOR)1.36,95%置信区间(95%CI)1.32 - 1.40],当前暴露(aOR 1.60,95%CI 1.52 - 1.69)和长期暴露时更高(aOR 1.65,95%CI 1.55 - 1.75)。未发现与RRT需求有显著关联。出乎意料的是,暴露于TW的患者死亡率较低(aOR 0.81,95%CI 0.71 - 0.93),这可能受其他原因影响。
当同时使用利尿剂、RAAS抑制剂和NSAIDs或安乃近时,应提高警惕,尤其是在老年患者等高危患者中。